Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP4396 |
| Synonyms | |
| Therapy Description |
ASP4396 comprises a E3 ubiquitin ligase-binding moiety linked to a moiety targeting KRAS G12D, which potentially targets KRAS G12D for proteasomal degradation, resulting in decreased growth of KRAS G12D-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP4396 | ASP-4396|ASP 4396 | KRAS G12D Inhibitor 25 | ASP4396 comprises a E3 ubiquitin ligase-binding moiety linked to a moiety targeting KRAS G12D, which potentially targets KRAS G12D for proteasomal degradation, resulting in decreased growth of KRAS G12D-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06364696 | Phase I | ASP4396 | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | Active, not recruiting | USA | 0 |